AU2020402049B2 - Preparation of Trifarotene and intermediates and polymorphs thereof - Google Patents

Preparation of Trifarotene and intermediates and polymorphs thereof Download PDF

Info

Publication number
AU2020402049B2
AU2020402049B2 AU2020402049A AU2020402049A AU2020402049B2 AU 2020402049 B2 AU2020402049 B2 AU 2020402049B2 AU 2020402049 A AU2020402049 A AU 2020402049A AU 2020402049 A AU2020402049 A AU 2020402049A AU 2020402049 B2 AU2020402049 B2 AU 2020402049B2
Authority
AU
Australia
Prior art keywords
substituted
formula
group
unsubstituted
trifarotene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020402049A
Other languages
English (en)
Other versions
AU2020402049A1 (en
Inventor
Avi Avramoff
Andrey DUSHKIN
Yulia KAFTANOV
Ilana Ozer
Hillel Pizem
Shani SHEFFER DEE-NOOR
Elliot Simhon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taro Pharmaceutical Industries Ltd
Original Assignee
Taro Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taro Pharmaceutical Industries Ltd filed Critical Taro Pharmaceutical Industries Ltd
Publication of AU2020402049A1 publication Critical patent/AU2020402049A1/en
Application granted granted Critical
Publication of AU2020402049B2 publication Critical patent/AU2020402049B2/en
Priority to AU2023222982A priority Critical patent/AU2023222982B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AU2020402049A 2019-12-11 2020-12-10 Preparation of Trifarotene and intermediates and polymorphs thereof Active AU2020402049B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023222982A AU2023222982B2 (en) 2019-12-11 2023-09-01 Preparation of trifarotene and intermediates and polymorphs thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962946943P 2019-12-11 2019-12-11
US62/946,943 2019-12-11
PCT/US2020/064365 WO2021119351A1 (en) 2019-12-11 2020-12-10 Preparation of trifarotene and intermediates and polymorphs thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023222982A Division AU2023222982B2 (en) 2019-12-11 2023-09-01 Preparation of trifarotene and intermediates and polymorphs thereof

Publications (2)

Publication Number Publication Date
AU2020402049A1 AU2020402049A1 (en) 2022-06-09
AU2020402049B2 true AU2020402049B2 (en) 2023-06-01

Family

ID=74141909

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020402049A Active AU2020402049B2 (en) 2019-12-11 2020-12-10 Preparation of Trifarotene and intermediates and polymorphs thereof
AU2023222982A Active AU2023222982B2 (en) 2019-12-11 2023-09-01 Preparation of trifarotene and intermediates and polymorphs thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023222982A Active AU2023222982B2 (en) 2019-12-11 2023-09-01 Preparation of trifarotene and intermediates and polymorphs thereof

Country Status (9)

Country Link
US (2) US11691946B2 (https=)
EP (2) EP4073035B1 (https=)
JP (3) JP7281016B2 (https=)
CN (1) CN114787129B (https=)
AU (2) AU2020402049B2 (https=)
CA (1) CA3161509A1 (https=)
ES (1) ES3037292T3 (https=)
IL (2) IL293800B2 (https=)
WO (1) WO2021119351A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL293800B2 (en) * 2019-12-11 2024-10-01 Taro Pharma Ind Preparation of trifarotene and intermediates and polymorphs thereof
CN117342993A (zh) * 2022-07-05 2024-01-05 石家庄迪斯凯威医药科技有限公司 一种曲法罗汀盐及其药物组合物和用途
CN115745913B (zh) * 2022-09-16 2024-05-24 南京迈诺威医药科技有限公司 曲法罗汀多晶型及其制备方法
JP2026507122A (ja) * 2023-02-28 2026-02-27 タロー・ファーマシューティカル・インダストリーズ・リミテッド トリファロテンを調製する方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006066978A1 (en) * 2004-12-23 2006-06-29 Galderma Research & Development Novel ligands that modulate rar receptors, and use thereof in human medicine and in cosmetics

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1248869A2 (en) * 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
WO2004083335A2 (en) * 2003-03-21 2004-09-30 University Of Rochester Glassy chiral-nematic liquid crystals and optical devices containing same
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
DK1817301T3 (da) * 2004-11-22 2012-02-27 Lilly Co Eli Forstærkere af glutamat-receptorer
GB2426247A (en) 2005-05-20 2006-11-22 Arrow Int Ltd Methods of preparing purine derivatives such as famciclovir
EP3475312B1 (en) * 2016-06-23 2020-05-27 Galderma S.A. Cyclodextrin-grafted cross-linked hyaluronic acid complexed with active drug substances and uses thereof
IL293800B2 (en) * 2019-12-11 2024-10-01 Taro Pharma Ind Preparation of trifarotene and intermediates and polymorphs thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006066978A1 (en) * 2004-12-23 2006-06-29 Galderma Research & Development Novel ligands that modulate rar receptors, and use thereof in human medicine and in cosmetics

Also Published As

Publication number Publication date
JP2026016786A (ja) 2026-02-03
IL293800A (en) 2022-08-01
JP2022550632A (ja) 2022-12-02
EP4552691A3 (en) 2025-09-10
IL293800B1 (en) 2024-06-01
CA3161509A1 (en) 2021-06-17
WO2021119351A1 (en) 2021-06-17
US20230051259A1 (en) 2023-02-16
CN114787129B (zh) 2025-07-04
AU2023222982B2 (en) 2025-01-02
EP4073035B1 (en) 2025-05-07
NZ788464A (en) 2024-07-05
IL293800B2 (en) 2024-10-01
EP4073035A1 (en) 2022-10-19
US11691946B2 (en) 2023-07-04
IL312356A (en) 2024-06-01
JP7281016B2 (ja) 2023-05-24
JP2023100974A (ja) 2023-07-19
EP4552691A2 (en) 2025-05-14
CN114787129A (zh) 2022-07-22
AU2023222982A1 (en) 2023-09-21
US20230278956A1 (en) 2023-09-07
AU2020402049A1 (en) 2022-06-09
ES3037292T3 (en) 2025-09-30

Similar Documents

Publication Publication Date Title
AU2020402049B2 (en) Preparation of Trifarotene and intermediates and polymorphs thereof
CN105859728B (zh) 一种依鲁替尼的制备方法
CN113214223A (zh) 一种富马酸伏诺拉生杂质的制备方法
JP7728795B2 (ja) キナーゼ阻害剤を調製するためのプロセス
KR20230145461A (ko) 리스디플람의 제조 방법
EP4673428A1 (en) Methods of preparing trifarotene
HK40077817A (zh) 曲法罗汀及其中间体和多晶型物的制备
CN115260012B (zh) 一种氟代醚的制备方法
HK40077817B (zh) 曲法罗汀及其中间体和多晶型物的制备
CN116987007A (zh) 一种对羟基苯甲腈的制备工艺
CN116332821A (zh) 一种5-(2-氟苯基)-1h-吡咯-3-甲腈的制备方法
CN111285880A (zh) 一种含双冠醚的开关化合物的制备和应用
CN110590771A (zh) 一种[1,5-a]-吡啶并咪唑-1-腈及其化学合成方法
CN119118913B (zh) 一种抗纤维化药物吡非尼酮的制备方法
CN114149452B (zh) 一种l-肌肽锌络合物的制备方法
Hirano et al. New [2+ 2]-and [4+ 4]-photodimerizations of 2-pyridones in an inclusion complex with a simple carboxylic acid host: a model of DNA damage by photodimerization of its thymine component
CN111718295B (zh) 一种高纯度米力农的制备方法
CN112010810B (zh) 一锅法制备高纯度利匹韦林中间体的方法
CN111718292B (zh) 一种米力农中间体化合物
CN117903111A (zh) 一种瑞卢戈利关键中间体的制备方法
CN110903245B (zh) 一种合成1-烷基-2-三氟甲基-5-氨基-1h-咪唑的关键中间体及其制备方法
CA3216107A1 (en) Process for synthesizing apremilast
TW202434235A (zh) ３－（４，５－二氯－２－（４－（三氟甲氧基）苯氧基）苯甲醯胺基）吡啶１－氧化物的製備方法
CN121914117A (zh) 一种制备四氢咪唑并吡嗪衍生物的方法
JP2026053018A (ja) ハロゲン化アルカンスルホニル化合物の製造方法、及び、多重結合含有化合物の製造方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)